EGFR and prostate carcinoma: Clinically, the overexpression of this receptor occurs in 80–90% of head and neck cancers, 60% of glioblastoma multiforme, and 40% of prostate cancers.15 EGFR is a transmembrane protein belonging to the family of receptors with tyrosine kinase activity that exists as a monomer in the cell membrane.